الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Pain is the most frequent cause of suffering and disability and the most common reason that people seek medical advice. It is a major symptom in many medical conditions, significantly interfering with a person’s quality of life and general functioning.
The management of the severe pain, most of the cancer patients experience, is a challenging matter that faces the treating physicians.
Analgesics or pain killers like opioids and NSAIDS may effectively control the pain to a limit but they have so much adverse effects that make the patient’s life miserable and also affect their survival.
The celiac plexus is the largest visceral plexus and is located deep in the retroperitoneum, over the anterolateral surface of the aorta and around the origin of the celiac trunk. It serves as a relay center for nociceptive impulses that originate from the upper abdominal viscera, from the stomach to the proximal transverse colon.
Celiac plexus neurolysis (CPN) is an effective method that can alleviate pain caused by abdominal malignancies which may be either primary or secondary. It leads to markedly decrease the analgesics daily dose or even give them away which can enhances the patient’s survival.
Celiac plexus neurolysis counts on destruction of the nerve cells in the celiac ganglia through injection of a neurolytic agent (ethanol) that can be delivered to the plexus using fluoroscopy, ultrasound guidance, CT guidance, endoscopic ultrasound guidance or by surgery.
The use of multidetector computed tomography (MDCT) for imaging guidance has superseded other modalities as it allows direct visualization of the spread of the injected nurolytic agent. It also allows accurate illustration.